Advertisement

Breast Cancer Research and Treatment

, Volume 167, Issue 3, pp 709–718 | Cite as

Randomized placebo-controlled pilot trial of omega 3 fatty acids for prevention of aromatase inhibitor-induced musculoskeletal pain

  • Maryam B. Lustberg
  • Tonya S. Orchard
  • Raquel Reinbolt
  • Rebecca Andridge
  • Xueliang Pan
  • Martha Belury
  • Rachel Cole
  • Amanda Logan
  • Rachel Layman
  • Bhuvaneswari Ramaswamy
  • Robert Wesolowski
  • Michael Berger
  • Elaine Patterson
  • Charles Loprinzi
  • Charles L. Shapiro
  • Lisa Yee
Clinical trial

Abstract

Purpose

Aromatase inhibitor (AI)-induced joint symptoms negatively impact drug adherence and quality of life in breast cancer survivors. Mechanisms underlying symptoms may include inflammation. It is hypothesized that n − 3 polyunsaturated fatty acids (PUFAs) have anti-inflammatory properties and may reduce symptoms.

Methods

We conducted a randomized, double-blind, placebo-controlled study comparing 4.3 g/day n − 3 PUFA supplements vs placebo for 24 weeks in postmenopausal breast cancer patients starting adjuvant AIs. Primary endpoints were adherence and tolerability; secondary outcomes included inflammatory cytokines and symptoms assessed by the Brief Pain Inventory short form (BPI-SF) and Functional Assessment of Cancer Treatment-Endocrine Symptoms (FACT-ES) at 0, 12, and 24 weeks.

Results

Forty-four women were randomized, of which 35 completed the study. Adherence was ≥ 88% based on these 35 patients with pill counts as well as change in red blood cell (RBC) n − 3 PUFAs. Common toxicities included grade 1 flatulence (55% of both groups) and belching (45% of n − 3 group). Mean pain severity scores (BPI-SF) did not change significantly by time or treatment arm. Quality of life, based on FACT-ES scores, significantly decreased within placebo (p = 0.04), but not the n − 3 group (p = 0.58), with a trend toward between-group differences (p = 0.06) at 12 weeks, but no significant differences at 24 weeks. RBC n − 3 levels were strongly positively correlated with FACT-ES at 12 weeks, but attenuated at 24 weeks.

Conclusion

High-dose n − 3 PUFA supplementation is feasible and well tolerated when administered with AIs. Additional studies are needed to evaluate efficacy in prevention of joint symptoms.

Keywords

Aromatase inhibitors Arthralgias Joint symptoms Omega-3 fatty acids Breast cancer survivors 

Notes

Acknowledgements

OSU Study #11022; ClinicalTrials.gov Identifier: NCT01478477.

Funding

Research reported in this publication was supported by the National Cancer Institute of the National Institutes of Health under the Award Number UG1CA189823 (Alliance for Clinical Trials in Oncology NCORP Grant). The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.

Compliance with ethical standards

Conflict of interest

All authors declare that they have no conflict of interest.

Ethical approval

All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.

Informed consent

Informed consent was obtained from all individual participants included in the study.

Supplementary material

10549_2017_4559_MOESM1_ESM.docx (29 kb)
Supplementary material 1 (DOCX 28 kb)

References

  1. 1.
    Hershman DL, Unger JM, Crew KD, Awad D, Dakhil SR, Gralow J, Greenlee H, Lew DL, Minasian LM, Till C et al (2015) Randomized multicenter placebo-controlled trial of omega-3 fatty acids for the control of aromatase inhibitor-induced musculoskeletal pain: SWOG S0927. J Clin Oncol 33(17):1910–1917CrossRefPubMedPubMedCentralGoogle Scholar
  2. 2.
    Henry NL, Giles JT, Ang D, Mohan M, Dadabhoy D, Robarge J, Hayden J, Lemler S, Shahverdi K, Powers P et al (1999) Prospective characterization of musculoskeletal symptoms in early stage breast cancer patients treated with aromatase inhibitors. Breast Cancer Res Treat 111(2):365–372CrossRefGoogle Scholar
  3. 3.
    Fallowfield LJ, Leaity SK, Howell A, Benson S, Cella D (1999) Assessment of quality of life in women undergoing hormonal therapy for breast cancer: validation of an endocrine symptom subscale for the FACT-B. Breast Cancer Rese Treat 55(2):189–199Google Scholar
  4. 4.
    Bruce B, Fries JF (2003) The stanford health assessment questionnaire: dimensions and practical applications. Health Qual Life Outcomes 1:20CrossRefPubMedPubMedCentralGoogle Scholar
  5. 5.
    Bruce B, Fries JF (2003) The Stanford Health Assessment Questionnaire: a review of its history, issues, progress, and documentation. J Rheumatol 30(1):167–178PubMedGoogle Scholar
  6. 6.
    Morales L, Pans S, Paridaens R, Westhovens R, Timmerman D, Verhaeghe J, Wildiers H, Leunen K, Amant F, Berteloot P, Smeets A, Van Limbergen E, Weltens C, Van den Bogaert W, De Smet L, Vergote I, Christiaens MR, Neven P (2007) Debilitating musculoskeletal pain and stiffness with letrozole and exemestane: associated tenosynovial changes on magnetic resonance imaging. Breast Cancer Res Treat 104(1):87–91CrossRefPubMedGoogle Scholar
  7. 7.
    Morales L, Pans S, Verschueren K, Van Calster B, Paridaens R, Westhovens R, Timmerman D, De Smet L, Vergote I, Christiaens MR, Neven P (2008) Prospective study to assess short-term intra-articular and tenosynovial changes in the aromatase inhibitor-associated arthralgia syndrome. J Clin Oncol 26(19):3147–3152CrossRefPubMedGoogle Scholar
  8. 8.
    Hershman DL, Kushi LH, Shao T, Buono D, Kershenbaum A, Tsai WY, Fehrenbacher L, Gomez SL, Miles S, Neugut AI (2010) Early discontinuation and nonadherence to adjuvant hormonal therapy in a cohort of 8769 early-stage breast cancer patients. J Clin Oncol 28(27):4120–4128CrossRefPubMedPubMedCentralGoogle Scholar
  9. 9.
    Fallowfield LJ, Bliss JM, Porter LS, Price MH, Snowdon CF, Jones SE, Coombes RC, Hall E (2006) Quality of life in the intergroup exemestane study: a randomized trial of exemestane versus continued tamoxifen after 2–3 years of tamoxifen in postmenopausal women with primary breast cancer. J Clin Oncol 24(6):910–917CrossRefPubMedGoogle Scholar
  10. 10.
    Goldberg RJ, Katz J (2007) A meta-analysis of the analgesic effects of omega-3 polyunsaturated fatty acid supplementation for inflammatory joint pain. Pain 129(1–2):210–223CrossRefPubMedGoogle Scholar
  11. 11.
    Fusi C, Materazzi S, Benemei S, Coppi E, Trevisan G, Marone IM, Minocci D, De Logu F, Tuccinardi T, Di Tommaso MR et al (2014) Steroidal and non-steroidal third-generation aromatase inhibitors induce pain-like symptoms via TRPA1. Nat Commun 5:5736CrossRefPubMedPubMedCentralGoogle Scholar
  12. 12.
    Park CK, Lu N, Xu ZZ, Liu T, Serhan CN, Ji RR (2011) Resolving TRPV1- and TNF-Â -mediated spinal cord synaptic plasticity and inflammatory pain with Neuroprotectin D1. J Neurosci 31(42):15072–15085CrossRefPubMedPubMedCentralGoogle Scholar
  13. 13.
    Ervin RB, Wright JD, Wang CY, Kennedy-Stephenson J (2004) Dietary intake of fats and fatty acids for the United States population: 1999–2000. Adv Data 348:1–6Google Scholar
  14. 14.
    Harris WS, Lemke SL, Hansen SN, Goldstein DA, DiRienzo MA, Su H, Nemeth MA, Taylor ML, Ahmed G, George C (2008) Stearidonic acid-enriched soybean oil increased the omega-3 index, an emerging cardiovascular risk marker. Lipids 43(9):805–811CrossRefPubMedGoogle Scholar
  15. 15.
    Belury MA, Kempa-Steczko A (1997) Conjugated linoleic acid modulates hepatic lipid composition in mice. Lipids 32(2):199–204CrossRefPubMedGoogle Scholar
  16. 16.
    Cao J, Schwichtenberg KA, Hanson NQ, Tsai MY (2006) Incorporation and clearance of omega-3 fatty acids in erythrocyte membranes and plasma phospholipids. Clin Chem 52(12):2265–2272CrossRefPubMedGoogle Scholar
  17. 17.
    Katan MB, Deslypere JP, vanBirgelen APJM, Penders M, Zegwaard M (1997) Kinetics of the incorporation of dietary fatty acids into serum cholesteryl esters, erythrocyte membranes, and adipose tissue: an 18-month controlled study. J Lipid Res 38(10):2012–2022PubMedGoogle Scholar
  18. 18.
    Diggle P, Heagerty P, Liang KY, Zeger SL (2002) Analysis of longitudinal data. Claredon Press, USA, OxfordGoogle Scholar
  19. 19.
    Kenward MG, Roger JH (1997) Small sample inference for fixed effects from restricted maximum likelihood. Biometrics 53(3):983–997CrossRefPubMedGoogle Scholar
  20. 20.
    Harris W (2007) Omega-3 fatty acids and cardiovascular disease: a case for omega-3 index as a new risk factor. Pharmacol Res 55(3):217–223CrossRefPubMedPubMedCentralGoogle Scholar
  21. 21.
    Henry NL, Griggs JJ (2015) The power of the placebo in symptom management. J Clin Oncol 33(17):1870–1872CrossRefPubMedGoogle Scholar
  22. 22.
    Hill CL, March LM, Aitken D, Lester SE, Battersby R, Hynes K, Fedorova T, Proudman SM, James M, Cleland LG et al (2016) Fish oil in knee osteoarthritis: a randomized clinical trial of low dose versus high dose. Ann Rheum Dis 75(1):23–29CrossRefPubMedGoogle Scholar
  23. 23.
    Proudman SM, James MJ, Spargo LD, Metcalf RG, Sullivan TR, Rischmueller M, Flabouris K, Wechalekar MD, Lee AT, Cleland LG (2015) Fish oil in recent onset rheumatoid arthritis: a randomised, double-blind controlled trial within algorithm-based drug use. Ann Rheum Dis 74(1):89–95CrossRefPubMedGoogle Scholar
  24. 24.
    Goldberg RJ, Katz J (2007) A meta-analysis of the analgesic effects of omega-3 polyunsaturated fatty acid supplementation for inflammatory joint pain. Pain 129(1–2):210–223CrossRefPubMedGoogle Scholar
  25. 25.
    Roke K, Mutch DM (2014) The role of FADS1/2 polymorphisms on cardiometabolic markers and fatty acid profiles in young adults consuming fish oil supplements. Nutrients 6(6):2290–2304CrossRefPubMedPubMedCentralGoogle Scholar
  26. 26.
    Rapaport MH, Nierenberg AA, Schettler PJ, Kinkead B, Cardoos A, Walker R, Mischoulon D (2016) Inflammation as a predictive biomarker for response to omega-3 fatty acids in major depressive disorder: a proof-of-concept study. Mol Psychiatr 21(1):71–79CrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2017

Authors and Affiliations

  • Maryam B. Lustberg
    • 1
    • 6
  • Tonya S. Orchard
    • 2
  • Raquel Reinbolt
    • 1
  • Rebecca Andridge
    • 3
  • Xueliang Pan
    • 4
  • Martha Belury
    • 2
  • Rachel Cole
    • 2
  • Amanda Logan
    • 1
  • Rachel Layman
    • 1
  • Bhuvaneswari Ramaswamy
    • 1
  • Robert Wesolowski
    • 1
  • Michael Berger
    • 1
  • Elaine Patterson
    • 1
  • Charles Loprinzi
    • 5
  • Charles L. Shapiro
    • 1
  • Lisa Yee
    • 1
  1. 1.Stefanie Spielman Comprehensive Breast CenterThe Ohio State UniversityColumbusUSA
  2. 2.Human Nutrition Program, Department of Human SciencesThe Ohio State UniversityColumbusUSA
  3. 3.Division of Biostatistics, College of Public HealthThe Ohio State UniversityColumbusUSA
  4. 4.The Ohio State University Center for BiostatisticsColumbusUSA
  5. 5.Mayo Clinic Cancer Center, Mayo ClinicRochesterUSA
  6. 6.The Ohio State University Oncology/HematologyColumbusUSA

Personalised recommendations